Interaction of mithramycin with chromatin

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Mithramycin (MTR) is an anti-cancer drug that inhibits macromolecular biosynthesis by interacting with DNA.
• In the presence of Mg2+, MTR forms two distinct complexes: Complex I (1:1 MTR:Mg2+) and Complex II (1:2 MTR:Mg2+).
• These MTR-Mg2+ complexes are expected to interact with chromatin, a complex of DNA and proteins, in eukaryotic systems.

Purpose of the Study:

• To investigate the interaction of MTR-Mg2+ complexes (Complex I and Complex II) with rat liver chromatin.
• To determine if these two complexes exhibit different binding behaviors with chromatin.
• To assess the influence of histone proteins on the binding of MTR-Mg2+ complexes to chromatin.

Main Methods:

• Absorption spectroscopy
• Fluorescence spectroscopy
• Study of MTR-Mg2+ complex interactions with isolated rat liver chromatin

Main Results:

• Mithramycin-magnesium complexes (Complex I and Complex II) demonstrate distinct binding potentials with chromatin.
• The observed differences in binding support the classification of Complex I and Complex II as unique molecular entities.
• Histone proteins within the chromatin significantly reduce the binding affinity and available binding sites for both MTR-Mg2+ complexes.

Conclusions:

• Mithramycin-magnesium complexes exhibit differential interactions with chromatin, influenced by their distinct stoichiometries.
• Histone proteins play a crucial role in modulating the interaction of MTR-Mg2+ complexes with chromatin.
• Understanding these interactions is vital for developing MTR-based anti-cancer therapies.